mal peg4 vc pab dmea

Mal-PEG4-VC-PAB-DMEA, a cleavable ADC linker incorporating a Maleimide moiety, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, DMEA-PNU-159682, is derived from metabolites of nemorubicin (MMDX) found in liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-drug conjugate linker, integrating the antitumor antibiotic Duocarmycin SA via the Mal-PEG4-VC-PAB-DMEA-Seco linker, aimed at targeted cancer therapy.

Mal-PEG4-VC-PAB-DMEA TFA, a degradable ADC linker with a maleimide group, is used for synthesizing antibody-drug conjugate (ADC) active molecules [1].

Mal-PEG4-VC-PAB-DMEA-duocarmycin SA is a thiol-reactive Drug-linker. Duocarmycin SA is a highly effective and orally active cytotoxic agent that can be used in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG4-VC-PAB-DMEA-duocarmycin-DM is a thiol-reactive Drug-linker. Duocarmycin DM is a DNA alkylating agent that can be used as a toxin for ADC conjugates and is employed in the synthesis of antibody-drug conjugates (ADCs).